Analyst Opinion Summary: Teekay Offshore Partners L.P. (TOO), Rockwell Medical, Inc. (RMTI)

Teekay Offshore Partners L.P. (NYSE:TOO) tinted gains of +0.77% (+0.01 points) to US$1.31. The volume of 0.51 Million shares climbed down over an trading activity of 513.48 Million shares. EPS ratio determined by looking at last 12 month figures is -0.48. Over the same time span, the stock marked US$3.12 as its best level and the lowest price reached was US$1.1. The corporation has a market cap of US$461.25 Million.

Teekay Offshore Partners L.P. (NYSE:TOO)’s earnings per share has been growing at a -25.7 percent rate over the past 5 year when average revenue increase was noted as 4.3 percent. The return on equity ratio or ROE stands at -13.7 percent while most common profitability ratio return on investment (ROI) was -2.6 percent. The company’s institutional ownership is monitored at 75.9 percent. The company’s net profit margin has achieved the current level of -15.5 percent and possesses 50.6 percent gross margin.

Daily Analyst Recommendations

A number of key analysts, polled by FactSet, shared their views about the current stock momentum. The forecast of 0 surveyed investment analysts covering the stock advises investors to Buy stake in the company. At present, 0 analysts call it Sell, while 1 think it is Hold. Recently, analysts have updated the overall rating to 3.5. 0 analysts recommended Overweight these shares while 1 recommended Underweight, according to FactSet data.

Rockwell Medical, Inc. (NASDAQ:RMTI) is worth US$213.62 Million and has recently fallen -0.84% to US$3.55. The latest exchange of 0.49 Million shares is below its average trading activity of 244.64 Million shares. The day began at US$3.5 but the price moved to US$3.5 at one point during the trading and finally capitulating to a session high of US$3.56. The stock tapped a 52-week high of US$6.92 while the mean 12-month price target for the shares is US$11.

Currently, the stock carries a price to earnings ratio of 0, a price to book ratio of 14.32, and a price to sales ratio of 3.48. For the past 5 years, the company’s revenue has grown 2.8%, while the company’s earnings per share has grown 28.1%. With an institutional ownership near 39.6%, it carries an earnings per share ratio of -0.62.

Inside Look At Analysts Reviews

Latest analyst recommendations could offer little help to investors. The stock is a Buy among 0 brokerage firms polled by Factset Research. At present, 0 analysts recommended Holding these shares while 0 recommended sell, according to FactSet data. 0 analysts call it Underweight, while 1 think it is Overweight. Recently, investment analysts covering the stock have updated the mean rating to 2.